About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 348167, 14 pages
http://dx.doi.org/10.1155/2013/348167
Review Article

Clinical Application of Magnetic Resonance Imaging in Management of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

1Center for Functional Onco-Imaging, Department of Radiological Sciences, University of California, Irvine, CA 92697-5020, USA
2Department of Radiology, E-Da Hospital and I-Shou University, Kaohsiung 82445, Taiwan

Received 5 January 2013; Accepted 17 May 2013

Academic Editor: David J. Yang

Copyright © 2013 Jeon-Hor Chen and Min-Ying Su. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Kaufmann, G. N. Hortobagyi, A. Goldhirsch et al., “Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update,” Journal of Clinical Oncology, vol. 24, no. 12, pp. 1940–1949, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Kaufmann, G. Von minckwitz, H. D. Bear et al., “Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006,” Annals of Oncology, vol. 18, no. 12, pp. 1927–1934, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. J. R. Gralow, H. J. Burstein, W. Wood et al., “Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease,” Journal of Clinical Oncology, vol. 26, no. 5, pp. 814–819, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Loibl, G. Von Minckwitz, G. Raab et al., “Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trial,” Annals of Surgical Oncology, vol. 13, no. 11, pp. 1434–1442, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. J. S. D. Mieog, J. A. Van Der Hage, and C. J. H. Van De Velde, “Neoadjuvant chemotherapy for operable breast cancer,” British Journal of Surgery, vol. 94, no. 10, pp. 1189–1200, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. P. Rastogi, S. J. Anderson, H. D. Bear et al., “Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27,” Journal of Clinical Oncology, vol. 26, no. 5, pp. 778–785, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. J. S. Jeruss, E. A. Mittendorf, S. L. Tucker et al., “Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy,” Journal of Clinical Oncology, vol. 26, no. 2, pp. 246–252, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. W. F. Symmans, F. Peintinger, C. Hatzis et al., “Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy,” Journal of Clinical Oncology, vol. 25, no. 28, pp. 4414–4422, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. A. M. Chen, F. Meric-Bernstam, K. K. Hunt et al., “Breast conservation after neoadjuvant chemotherapy: the M.D. Anderson cancer center experience,” Journal of Clinical Oncology, vol. 22, no. 12, pp. 2303–2312, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. F. Peintinger, W. F. Symmans, A. M. Gonzalez-Angulo et al., “The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy,” Cancer, vol. 107, no. 6, pp. 1248–1254, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. J. L. Oh, M. J. Dryden, W. A. Woodward et al., “Locoregional control of clinically diagnosed multifocal or multicentric breast cancer after neoadjuvant chemotherapy and locoregional therapy,” Journal of Clinical Oncology, vol. 24, no. 31, pp. 4971–4975, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. A. M. Chen, F. Meric-Bernstam, K. K. Hunt et al., “Breast conservation after neoadjuvant chemotherapy: a prognostic index for clinical decision-making,” Cancer, vol. 103, no. 4, pp. 689–695, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. S. J. Vinnicombe, A. D. MacVicar, R. L. Guy et al., “Primary breast cancer: mammographic changes after neoadjuvant chemotherapy, with pathologic correlation,” Radiology, vol. 198, no. 2, pp. 333–340, 1996. View at Scopus
  14. H. Junkermann and D. Von Fournier, “Imaging procedures for assessment of the response of mammary carcinoma to preoperative chemotherapy,” Radiologe, vol. 37, no. 9, pp. 726–732, 1997. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Herrada, R. B. Iyer, E. N. Atkinson, N. Sneige, A. U. Buzdar, and G. N. Hortobagyi, “Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma,” Clinical Cancer Research, vol. 3, no. 9, pp. 1565–1569, 1997. View at Scopus
  16. L. Esserman, E. Kaplan, S. Partridge et al., “MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer,” Annals of Surgical Oncology, vol. 8, no. 6, pp. 549–559, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. C. Balu-Maestro, C. Chapellier, A. Bleuse, I. Chanalet, C. Chauvel, and R. Largillier, “Imaging in evaluation of response to neoadjuvant breast cancer treatment benefits of MRI,” Breast Cancer Research and Treatment, vol. 72, no. 2, pp. 145–152, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Rieber, H.-. Brambs, A. Gabelmann, V. Heilmann, R. Kreienberg, and T. Kühn, “Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy,” European Radiology, vol. 12, no. 7, pp. 1711–1719, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. P. L. Choyke, A. J. Dwyer, and M. V. Knopp, “Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging,” Journal of Magnetic Resonance Imaging, vol. 17, no. 5, pp. 509–520, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. P. S. Tofts and A. G. Kermode, “Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts,” Magnetic Resonance in Medicine, vol. 17, no. 2, pp. 357–367, 1991. View at Scopus
  21. P. S. Tofts, “Modeling tracer kinetics in dynamic Gd-DTPA MR imaging,” Journal of Magnetic Resonance Imaging, vol. 7, no. 1, pp. 91–101, 1997. View at Publisher · View at Google Scholar · View at Scopus
  22. M. W. Ah-See, A. Makris, N. J. Taylor et al., “Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer,” Clinical Cancer Research, vol. 14, no. 20, pp. 6580–6589, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. C. K. Kuhl, H. B. Bieling, J. Gieseke et al., “Healthy premenopausal breast parenchyma in dynamic contrast-enhanced MR imaging of the breast: normal contrast medium enhancement and cyclical-phase dependency,” Radiology, vol. 203, no. 1, pp. 137–144, 1997. View at Scopus
  24. M. Müller-Schimpfle, K. Ohmenhäuser, P. Stoll, K. Dietz, and C. D. Claussen, “Menstrual cycle and age: influence on parenchymal contrast medium enhancement in MR imaging of the breast,” Radiology, vol. 203, no. 1, pp. 145–149, 1997. View at Scopus
  25. P. A. Baltzer, M. Dietzel, T. Vag et al., “Clinical MR mammography: impact of hormonal status on background enhancement and diagnostic accuracy,” RoFo Fortschritte auf dem Gebiet der Rontgenstrahlen und der Bildgebenden Verfahren, vol. 183, no. 5, pp. 441–447, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. S. A. Jansen, V. C. Lin, M. L. Giger, H. Li, G. S. Karczmar, and G. M. Newstead, “Normal parenchymal enhancement patterns in women undergoing MR screening of the breast,” European Radiology, vol. 21, no. 7, pp. 1374–1382, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. C. Klifa, S. Suzuki, S. Aliu et al., “Quantification of background enhancement in breast magnetic resonance imaging,” Journal of Magnetic Resonance Imaging, vol. 33, no. 5, pp. 1229–1234, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. T. Uematsu, M. Kasami, and J. Watanabe, “Does the degree of background enhancement in breast MRI affect the detection and staging of breast cancer?” European Radiology, vol. 21, no. 11, pp. 2261–2267, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. T. Uematsu, M. Kasami, and J. Watanabe, “Background enhancement of mammary glandular tissue on breast dynamic MRI: imaging features and effect on assessment of breast cancer extent,” Breast Cancer, vol. 19, no. 3, pp. 259–265, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. V. King, J. D. Brooks, J. L. Bernstein, A. S. Reiner, M. C. Pike, and E. A. Morris, “Background parenchymal enhancement at breast MR imaging and breast cancer risk,” Radiology, vol. 260, no. 1, pp. 50–60, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Chen, K. Nie, S. Bahri et al., “Decrease in breast density in the contralateral normal breast of patients receiving neoadjuvant chemotherapy: MR imaging evaluation,” Radiology, vol. 255, no. 1, pp. 44–52, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. T. Uematsu, M. Kasami, and S. Yuen, “Neoadjuvant chemotherapy for breast cancer: correlation between the baseline MR imaging findings and responses to therapy,” European Radiology, vol. 20, no. 10, pp. 2315–2322, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. H. Kawashima, M. Inokuchi, H. Furukawa, and S. Kitamura, “Triple-negative breast cancer. Are the imaging findings different between responders and nonresponders to neoadjuvant chemotherapy?” Academic Radiology, vol. 18, no. 8, pp. 963–969, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. R. Prevos, M. L. Smidt, V. C. Tjan-Heijnen et al., “Pre-treatment differences and early response monitoring of neoadjuvant chemotherapy in breast cancer patients using magnetic resonance imaging: a systematic review,” European Radiology, vol. 22, no. 12, pp. 2607–2616, 2012.
  35. M. D. Pickles, D. J. Manton, M. Lowry, and L. W. Turnbull, “Prognostic value of pre-treatment DCE-MRI parameters in predicting disease free and overall survival for breast cancer patients undergoing neoadjuvant chemotherapy,” European Journal of Radiology, vol. 71, no. 3, pp. 498–505, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. M. G. Heldahl, T. F. Bathen, J. Rydland et al., “Prognostic value of pretreatment dynamic contrast-enhanced MR imaging in breast cancer patients receiving neoadjuvant chemotherapy: overall survival predicted from combined time course and volume analysis,” Acta Radiologica, vol. 51, no. 6, pp. 604–612, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. S. P. Li, A. Makris, M. J. Beresford et al., “Use of dynamic contrast-enhanced MR imaging to predict survival in patients with primary breast cancer undergoing neoadjuvant chemotherapy,” Radiology, vol. 260, no. 1, pp. 68–78, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. D. J. Manton, A. Chaturvedi, A. Hubbard et al., “Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy,” British Journal of Cancer, vol. 94, no. 3, pp. 427–435, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. A. R. Padhani, C. Hayes, L. Assersohn et al., “Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced mr imaging: initial clinical results,” Radiology, vol. 239, no. 2, pp. 361–374, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. M. D. Pickles, M. Lowry, D. J. Manton, P. Gibbs, and L. W. Turnbull, “Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy,” Breast Cancer Research and Treatment, vol. 91, no. 1, pp. 1–10, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. H. J. Yu, J. Chen, R. S. Mehta, O. Nalcioglu, and M. Su, “MRI measurements of tumor size and pharmacokinetic parameters as early predictors of response in breast cancer patients undergoing neoadjuvant anthracycline chemotherapy,” Journal of Magnetic Resonance Imaging, vol. 26, no. 3, pp. 615–623, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. C. de Bazelaire, R. Calmon, I. Thomassin et al., “Accuracy of perfusion MRI with high spatial but low temporal resolution to assess invasive breast cancer response to neoadjuvant chemotherapy: a retrospective study,” BMC Cancer, vol. 11, article no. 361, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Mehta, N. P. Hughes, F. M. Buffa et al., “Assessing early therapeutic response to bevacizumab in primary breast cancer using magnetic resonance imaging and gene expression profiles,” Journal of the National Cancer Institute, vol. 2011, no. 43, pp. 71–74, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. J. C. Miller, H. H. Pien, D. Sahani, A. G. Sorensen, and J. H. Thrall, “Imaging angiogenesis: application and potential for drug development,” Journal of the National Cancer Institute, vol. 97, no. 3, pp. 172–187, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. A. R. Padhani and M. O. Leach, “Antivascular cancer treatments: functional assessments by dynamic contrast-enhanced magnetic resonance imaging,” Abdominal Imaging, vol. 30, no. 3, pp. 324–341, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. S. Rehman and G. C. Jayson, “Molecular imaging of antiangiogenic agents,” Oncologist, vol. 10, no. 2, pp. 92–103, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. O. M. Hahn, C. Yang, M. Medved et al., “Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma,” Journal of Clinical Oncology, vol. 26, no. 28, pp. 4572–4578, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Moreno-Aspitia, R. F. Morton, D. W. Hillman et al., “Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: north central cancer treatment group and mayo clinic trial n0336,” Journal of Clinical Oncology, vol. 27, no. 1, pp. 11–15, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. J. P. B. O'Connor, A. Jackson, G. J. M. Parker, and G. C. Jayson, “DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents,” British Journal of Cancer, vol. 96, no. 2, pp. 189–195, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. A. Thukral, D. M. Thomasson, C. K. Chow et al., “Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab - Initial experience,” Radiology, vol. 244, no. 3, pp. 727–735, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. K. A. Kvistad, I. J. Bakken, I. S. Gribbestad, et al., “Characterization of neoplastic and normal human breast tissues with in vivo 1 H MR spectroscopy,” Journal of Magnetic Resonance Imaging, vol. 10, pp. 159–164, 1999.
  52. N. R. Jagannathan, M. Kumar, V. Seenu et al., “Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer,” British Journal of Cancer, vol. 84, no. 8, pp. 1016–1022, 2001. View at Publisher · View at Google Scholar · View at Scopus
  53. S. Meisamy, P. J. Bolan, E. H. Baker et al., “Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo 1H MR spectroscopy - A pilot study at 4 T,” Radiology, vol. 233, no. 2, pp. 424–431, 2004. View at Publisher · View at Google Scholar · View at Scopus
  54. H. M. Baek, J. H. Chen, O. Nalcioglu, and M. Y. Su, “Proton MR spectroscopy for monitoring early treatment response of breast cancer to neo-adjuvant chemotherapy,” Annals of Oncology, vol. 19, no. 5, pp. 1022–1024, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. H. Baek, J. Chen, K. Nie et al., “Predicting pathologic response to neoadjuvant chemotherapy in breast cancer by using MR imaging and quantitative 1H MR spectroscopy,” Radiology, vol. 251, no. 3, pp. 653–662, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. M. Tozaki, M. Sakamoto, Y. Oyama, K. Maruyama, and E. Fukuma, “Predicting pathological response to neoadjuvant chemotherapy in breast cancer with quantitative 1H MR spectroscopy using the external standard method,” Journal of Magnetic Resonance Imaging, vol. 31, no. 4, pp. 895–902, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. M. Tozaki, Y. Oyama, and E. Fukuma, “Preliminary study of early response to neoadjuvant chemotherapy after the first cycle in breast cancer: comparison of 1H magnetic resonance spectroscopy with diffusion magnetic resonance imaging,” Japanese Journal of Radiology, vol. 28, no. 2, pp. 101–109, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. T. F. Bathen, M. G. Heldahl, B. Sitter et al., “In vivo MRS of locally advanced breast cancer: characteristics related to negative or positive choline detection and early monitoring of treatment response,” Magma, vol. 24, no. 6, pp. 347–357, 2011. View at Scopus
  59. P. E. Sijens, H. K. Wijrdeman, M. A. Moerland, C. J. G. Bakker, J. W. A. H. Vermeulen, and P. R. Luyten, “Human breast cancer in vivo: H-1 and P-31 MR spectroscopy at 1.5 T,” Radiology, vol. 169, no. 3, pp. 615–620, 1988. View at Scopus
  60. M. Albert Thomas, N. Binesh, K. Yue, and N. Debruhl, “Volume-localized two-dimensional correlated magnetic resonance spectroscopy of human breast cancer,” Journal of Magnetic Resonance Imaging, vol. 14, no. 2, pp. 181–186, 2001. View at Publisher · View at Google Scholar · View at Scopus
  61. M. Kumar, N. R. Jagannathan, V. Seenu, S. N. Dwivedi, P. K. Julka, and G. K. Rath, “Monitoring the therapeutic response of locally advanced breast cancer patients: sequential in vivo proton MR spectroscopy study,” Journal of Magnetic Resonance Imaging, vol. 24, no. 2, pp. 325–332, 2006. View at Publisher · View at Google Scholar · View at Scopus
  62. E. A. M. O'Flynn and N. M. DeSouza, “Correction: functional magnetic resonance: biomarkers of response in breast cancer,” Breast Cancer Research, vol. 13, no. 1, article 204, 2011. View at Publisher · View at Google Scholar · View at Scopus
  63. L. Wu, J. Hu, H. Gu, J. Hua, J. Chen, and J. Xu, “Can diffusion-weighted MR imaging and contrast-enhanced MR imaging precisely evaluate and predict pathological response to neoadjuvant chemotherapy in patients with breast cancer?” Breast Cancer Research and Treatment, vol. 135, no. 1, pp. 17–28, 2012. View at Publisher · View at Google Scholar · View at Scopus
  64. M. D. Pickles, P. Gibbs, M. Lowry, and L. W. Turnbull, “Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer,” Magnetic Resonance Imaging, vol. 24, no. 7, pp. 843–847, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. U. Sharma, K. K. A. Danishad, V. Seenu, and N. R. Jagannathan, “Longitudinal study of the assessment by MRI and diffusion-weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy,” NMR in Biomedicine, vol. 22, no. 1, pp. 104–113, 2009. View at Publisher · View at Google Scholar · View at Scopus
  66. L. Nilsen, A. Fangberget, O. Geier, D. R. Olsen, and T. Seierstad, “Diffusion-weighted magnetic resonance imaging for pretreatment prediction and monitoring of treatment response of patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy,” Acta Oncologica, vol. 49, no. 3, pp. 354–360, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. K. C. Lee, B. A. Moffat, A. F. Schott et al., “Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy,” Clinical Cancer Research, vol. 13, no. 2, part 1, pp. 443–450, 2007. View at Publisher · View at Google Scholar · View at Scopus
  68. P. Belli, M. Costantini, C. Ierardi et al., “Diffusion-weighted imaging in evaluating the response to neoadjuvant breast cancer treatment,” Breast Journal, vol. 17, no. 6, pp. 610–619, 2011. View at Publisher · View at Google Scholar · View at Scopus
  69. L. R. Jensen, B. Garzon, M. G. Heldahl, T. F. Bathen, S. Lundgren, and I. S. Gribbestad, “Diffusion-weighted and dynamic contrast-enhanced MRI in evaluation of early treatment effects during neoadjuvant chemotherapy in breast cancer patients,” Journal of Magnetic Resonance Imaging, vol. 34, no. 5, pp. 1099–1109, 2011. View at Publisher · View at Google Scholar · View at Scopus
  70. M. Kawamura, H. Satake, S. Ishigaki, A. Nishio, M. Sawaki, and S. Naganawa, “Early prediction of response to neoadjuvant chemotherapy for locally advanced breast cancer using MRI,” Nagoya Journal of Medical Science, vol. 73, no. 3-4, pp. 147–156, 2011. View at Scopus
  71. A. Fangberget, L. B. Nilsen, K. H. Hole et al., “Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging,” European Radiology, vol. 21, no. 6, pp. 1188–1199, 2011. View at Publisher · View at Google Scholar · View at Scopus
  72. S. H. Park, W. K. Moon, N. Cho et al., “Comparison of diffusion-weighted MR imaging and FDG PET/CT to predict pathological complete response to neoadjuvant chemotherapy in patients with breast cancer,” European Radiology, vol. 22, no. 1, pp. 18–25, 2012. View at Publisher · View at Google Scholar · View at Scopus
  73. S. H. Park, W. K. Moon, N. Cho et al., “Diffusion-weighted MR imaging: pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer,” Radiology, vol. 257, no. 1, pp. 56–63, 2010. View at Publisher · View at Google Scholar · View at Scopus
  74. C. Iacconi, M. Giannelli, C. Marini et al., “The role of mean diffusivity (MD) as a predictive index of the response to chemotherapy in locally advanced breast cancer: A Preliminary Study,” European Radiology, vol. 20, no. 2, pp. 303–308, 2010. View at Publisher · View at Google Scholar · View at Scopus
  75. P. D. Humphries, N. J. Sebire, M. J. Siegel, and Ø. E. Olsen, “Tumors in pediatric patients at diffusion-weighted MR imaging: apparent diffusion coefficient and tumor cellularity,” Radiology, vol. 245, no. 3, pp. 848–854, 2007. View at Publisher · View at Google Scholar · View at Scopus
  76. A. C. Guo, T. J. Cummings, R. C. Dash, and J. M. Provenzale, “Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics,” Radiology, vol. 224, no. 1, pp. 177–183, 2002. View at Scopus
  77. R. Woodhams, S. Kakita, H. Hata et al., “Identification of residual breast carcinoma following neoadjuvant chemotherapy: diffusion-weighted imaging—comparison with contrast-enhanced MR imaging and pathologic findings,” Radiology, vol. 254, no. 2, pp. 357–366, 2010. View at Publisher · View at Google Scholar · View at Scopus
  78. H. G. Moon, W. Han, J. Q. Lee, et al., “Age and HER2 expression status affect MRI accuracy in predicting residual tumor extent after neo-adjuvant systemic treatment,” Annals of Oncology, vol. 20, no. 4, pp. 636–641, 2009. View at Publisher · View at Google Scholar · View at Scopus
  79. S. C. Partridge, J. E. Gibbs, Y. Lu, L. J. Esserman, D. Sudilovsky, and N. M. Hylton, “Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy,” American Journal of Roentgenology, vol. 179, no. 5, pp. 1193–1199, 2002. View at Scopus
  80. S. Orel, “Who should have breast magnetic resonance imaging evaluation?” Journal of Clinical Oncology, vol. 26, no. 5, pp. 703–711, 2008. View at Publisher · View at Google Scholar · View at Scopus
  81. J. H. Chen, B. Feig, G. Agrawal et al., “MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy,” Cancer, vol. 112, no. 7, pp. 17–26, 2008. View at Scopus
  82. S. Bahri, J. Chen, R. S. Mehta et al., “Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab,” Annals of Surgical Oncology, vol. 16, no. 6, pp. 1619–1628, 2009. View at Publisher · View at Google Scholar · View at Scopus
  83. C. E. Loo, M. E. Straver, S. Rodenhuis et al., “Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype,” Journal of Clinical Oncology, vol. 29, no. 6, pp. 660–666, 2011. View at Publisher · View at Google Scholar · View at Scopus
  84. J. Chen, S. Bahri, R. S. Mehta et al., “Breast cancer: evaluation of response to neoadjuvant chemotherapy with 3.0-T MR imaging,” Radiology, vol. 261, no. 3, pp. 735–743, 2011. View at Publisher · View at Google Scholar · View at Scopus
  85. K. P. McGuire, J. Toro-Burguete, H. Dang et al., “MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?” Annals of Surgical Oncology, vol. 18, no. 11, pp. 3149–3154, 2011. View at Publisher · View at Google Scholar · View at Scopus
  86. H. Nakahara, Y. Yasuda, E. Machida et al., “MR and US imaging for breast cancer patients who underwent conservation surgery after neoadjuvant chemotherapy: comparison of triple negative breast cancer and other intrinsic subtypes,” Breast Cancer, vol. 18, no. 3, pp. 152–160, 2011. View at Publisher · View at Google Scholar · View at Scopus
  87. L. M. Marcos de Paz, A. Tejerina Bernal, M. L. Arranz Merino, and V. Calvo de Juan, “Breast MR imaging changes after neoadjuvant chemotherapy: correlation with molecular subtypes,” Radiologia, vol. 54, no. 5, pp. 442–448, 2012. View at Publisher · View at Google Scholar · View at Scopus
  88. J. De Los Santos, W. Bernreuter, K. Keene et al., “Accuracy of breast magnetic resonance imaging in predicting pathologic response in patients treated with neoadjuvant chemotherapy,” Clinical Breast Cancer, vol. 11, no. 5, pp. 312–319, 2011. View at Publisher · View at Google Scholar · View at Scopus
  89. A. Kuzucan, J. Chen, S. Bahri et al., “Diagnostic performance of magnetic resonance imaging for assessing tumor response in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy is associated with molecular biomarker profile,” Clinical Breast Cancer, vol. 12, no. 2, pp. 110–118, 2012. View at Publisher · View at Google Scholar · View at Scopus
  90. J. H. Chen, R. S. Mehta, P. M. Carpenter, O. Nalcioglu, and M. Y. Su, “Magnetic resonance imaging in predicting pathological response of triple negative breast cancer following neoadjuvant chemotherapy,” Journal of Clinical Oncology, vol. 25, no. 35, pp. 5667–5669, 2007. View at Publisher · View at Google Scholar · View at Scopus
  91. D. G. Norris, “High Field Human Imaging,” Journal of Magnetic Resonance Imaging, vol. 18, no. 5, pp. 519–529, 2003. View at Publisher · View at Google Scholar · View at Scopus
  92. N. Morakkabati-Spitz, J. Gieseke, C. Kuhl et al., “MRI of the pelvis at 3 T: very high spatial resolution with sensitivity encoding and flip-angle sweep technique in clinically acceptable scan time,” European Radiology, vol. 16, no. 3, pp. 634–641, 2006. View at Publisher · View at Google Scholar · View at Scopus
  93. C. K. Kuhl, H. Kooijman, J. Gieseke, and H. H. Schild, “Effect of B1 inhomogeneity on breast MR imaging at 3.0 T,” Radiology, vol. 244, no. 3, pp. 929–930, 2007. View at Publisher · View at Google Scholar · View at Scopus
  94. R. M. Mann, C. K. Kuhl, K. Kinkel, and C. Boetes, “Breast MRI: guidelines from the European Society of Breast Imaging,” European Radiology, vol. 18, no. 7, pp. 1307–1318, 2008. View at Publisher · View at Google Scholar · View at Scopus
  95. C. A. Azlan, P. Di Giovanni, T. S. Ahearn, S. I. K. Semple, F. J. Gilbert, and T. W. Redpath, “B1 transmission-field inhomogeneity and enhancement ratio errors in dynamic contrast-enhanced MRI (DCE-MRI) of the breast at 3T,” Journal of Magnetic Resonance Imaging, vol. 31, no. 1, pp. 234–239, 2010. View at Publisher · View at Google Scholar · View at Scopus
  96. M. G. Heldahl, S. Lundgren, L. R. Jensen, I. S. Gribbestad, and T. F. Bathen, “Monitoring neoadjuvant chemotherapy in breast cancer patients: improved MR assessment at 3 T?” Journal of Magnetic Resonance Imaging, vol. 34, no. 3, pp. 547–556, 2011. View at Publisher · View at Google Scholar · View at Scopus
  97. M. A. Korteweg, W. B. Veldhuis, F. Visser et al., “Feasibility of 7 Tesla breast magnetic resonance imaging determination of intrinsic sensitivity and high-resolution magnetic resonance imaging, diffusion-weighted imaging, and 1H-magnetic resonance spectroscopy of breast cancer patients receiving neoadjuvant therapy,” Investigative Radiology, vol. 46, no. 6, pp. 370–376, 2011. View at Publisher · View at Google Scholar · View at Scopus
  98. J. Chen, B. A. Feig, D. J. Hsiang et al., “Impact of MRI-evaluated neoadjuvant chemotherapy response on change of surgical recommendation in breast cancer,” Annals of Surgery, vol. 249, no. 3, pp. 448–454, 2009. View at Publisher · View at Google Scholar · View at Scopus
  99. E. A. Morris, “Diagnostic breast MR imaging: current status and future directions,” Radiologic Clinics of North America, vol. 45, no. 5, pp. 863–880, 2007. View at Publisher · View at Google Scholar · View at Scopus
  100. C. Kuhl, “The current status of breast MR imaging—part I: choice of technique, image interpretation, diagnostic accuracy, and transfer to clinical practice,” Radiology, vol. 244, no. 2, pp. 356–378, 2007. View at Publisher · View at Google Scholar · View at Scopus
  101. C. K. Kuhl, “Current status of breast MR imaging—part 2: clinical applications,” Radiology, vol. 244, no. 3, pp. 672–691, 2007. View at Publisher · View at Google Scholar · View at Scopus
  102. R. Cubuk, N. Tasali, B. Narin, F. Keskiner, L. Celik, and S. Guney, “Correlation between breast density in mammography and background enhancement in MR mammography,” Radiologia Medica, vol. 115, no. 3, pp. 434–441, 2010. View at Publisher · View at Google Scholar · View at Scopus
  103. E. S. Ko, B. H. Lee, H. Y. Choi, R. B. Kim, and W. Noh, “Background enhancement in breast MR: correlation with breast density in mammography and background echotexture in ultrasound,” European Journal of Radiology, vol. 80, no. 3, pp. 719–723, 2011. View at Publisher · View at Google Scholar · View at Scopus
  104. J. Hattangadi, C. Park, J. Rembert et al., “Breast stromal enhancement on MRI is associated with response to neoadjuvant chemotherapy,” American Journal of Roentgenology, vol. 190, no. 6, pp. 1630–1636, 2008. View at Publisher · View at Google Scholar · View at Scopus
  105. K. Kerlikowske, L. Ichikawa, D. L. Miglioretti et al., “Longitudinal measurement of clinical mammographic breast density to improve estimation of breast cancer risk,” Journal of the National Cancer Institute, vol. 99, no. 5, pp. 386–395, 2007. View at Publisher · View at Google Scholar · View at Scopus
  106. J. Cuzick, J. Warwick, E. Pinney et al., “Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study,” Journal of the National Cancer Institute, vol. 103, no. 9, pp. 744–752, 2011. View at Publisher · View at Google Scholar · View at Scopus
  107. S. J. Schnitt and L. C. Collins, Biopsy Interpretation of the Breast Treatment Effects, Lippincott Williams and Wilkins, Philadelphia, Pa, USA, 2009.
  108. S. E. Minton and P. N. Munster, “Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer,” Cancer Control, vol. 9, no. 6, pp. 466–472, 2002. View at Scopus
  109. Y. Tham, K. Sexton, H. Weiss, R. Elledge, L. C. Friedman, and R. Kramer, “The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane,” American Journal of Clinical Oncology, vol. 30, no. 2, pp. 126–132, 2007. View at Publisher · View at Google Scholar · View at Scopus